文献速递神经骨肌儿科影像MR

年龄是否影响钆毒性及脑与骨组织中的钆沉积:幼年与成年大鼠中钆特酸与钆双胺的比较研究

Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats.
PubMed 文献 · Invest Radiol · 2019-01-01

在幼年和成年大鼠中比较线性钆双胺与大环状钆特酸反复给药后的组织钆残留,钆双胺组脑深部小脑核T1高信号持续存在且脑、骨、皮肤总钆浓度较钆特酸组高10至30倍,骨髓分布受年龄影响,未见组织病理学或发育行为显著改变,作者认为需进一步研究骨髓钆滞留风险。

要点

  • 钆双胺组幼年和成年大鼠均出现深部小脑核持续T1高信号,钆特酸组无论年龄均未出现。
  • 脑、骨、皮肤总钆浓度钆双胺组较钆特酸组高10至30倍,骨髓分布受年龄影响。
  • 幼年大鼠钆双胺组出现一过性皮肤病变(雌性5/5、雄性2/4),成年大鼠未见。

核心结论

  • 大环状钆特酸给药后无论年龄均未出现深部小脑核T1高信号,而线性钆双胺给药后出现;幼年与成年大鼠钆双胺组皮肤、脑、骨总钆滞留相似且性别无影响,但骨髓钆分布受年龄影响。

研究设计与样本

  • 在健康成年和幼年大鼠中经静脉给予20次等效人体临床剂量(累积剂量12 mmol Gd/kg)的钆特酸或钆双胺,幼年大鼠另设生理盐水对照组。

关键影像表现/征象

  • 钆双胺组幼年大鼠出现一过性皮肤病变,成年大鼠未见;钆双胺组仅见深部小脑核持续T1高信号,钆特酸组未见。

局限性

  • 原文指出需进一步研究以评估滞留钆的形式。
  • 原文指出需进一步研究以探讨幼年动物接受钆双胺后骨髓钆滞留的潜在风险。
  • 原文提到高架十字迷宫测试中钆双胺组较其他组观察到焦虑样效应趋势,但无统计学显著性。
  • 原文提到平衡木测试中钆双胺组大量试验被排除,主要因雄性大鼠未完全穿过横梁,可能也反映焦虑样效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The main objective of the study was to assess the effect of age on target tissue total gadolinium (Gd) retention after repeated administration of gadodiamide (linear) or gadoterate (macrocyclic) Gd-based contrast agent (GBCA) in rats. The secondary objective was to assess the potential developmental and long-term consequences of GBCA administration during neonatal and juvenile periods.

MATERIALS AND METHODS: A total of 20 equivalent human clinical doses (cumulated dose, 12 mmol Gd/kg) of either gadoterate or gadodiamide were administered concurrently by the intravenous route to healthy adult and juvenile rats. Saline was administered to juvenile rats forming the control group. In juvenile rats, the doses were administered from postnatal day 12, that is, once the blood-brain barrier is functional as in humans after birth. The tests were conducted on 5 juvenile rats per sex and per group and on 3 adult animals per sex and per group. T1-weighted magnetic resonance imaging of the cerebellum was performed at 4.7 T during both the treatment and treatment-free periods. Behavioral tests were performed in juvenile rats. Rats were euthanatized at 11 to 12 weeks (ie, approximately 3 months) after the last administration. Total Gd concentrations were measured in plasma, skin, bone, and brain by inductively coupled plasma mass spectrometry. Cerebellum samples from the juvenile rats were characterized by histopathological examination (including immunohistochemistry for glial fibrillary acidic protein or GFAP, and CD68). Lipofuscin pigments were also studied by fluorescence microscopy. All tests were performed blindly on randomized animals.

RESULTS: Transient skin lesions were observed in juvenile rats (5/5 females and 2/4 males) and not in adult rats having received gadodiamide. Persisting (up to completion of the study) T1 hyperintensity in the deep cerebellar nuclei (DCNs) was observed only in gadodiamide-treated rats. Quantitatively, a slightly higher progressive increase in the DCN/brain stem ratio was observed in adult rats compared with juvenile rats, whereas no difference was noted visually. In all tissues, total Gd concentrations were higher (10- to 30-fold higher) in the gadodiamide-treated groups than in the gadoterate groups. No age-related differences were observed except in bone marrow where total Gd concentrations in gadodiamide-treated juvenile rats were higher than those measured in adults and similar to those measured in cortical bone tissue. No significant treatment-related effects were observed in histopathological findings or in development, behavior, and biochemistry parameters. However, in the elevated plus maze test, a trend toward an anxiogenic effect was observed in the gadodiamide group compared with other groups (nonsignificant). Moreover, in the balance beam test, a high number of trials were excluded in the gadodiamide group because rats (mainly males) did not completely cross the beam, which may also reflect an anxiogenic effect.

CONCLUSIONS: No T1 hyperintensity was observed in the DCN after administration of the macrocyclic GBCA gadoterate regardless of age as opposed to administration of the linear GBCA gadodiamide. Repeated administration of gadodiamide in neonatal and juvenile rats resulted in similar total Gd retention in the skin, brain, and bone to that in adult rats with sex having no effect, whereas Gd distribution in bone marrow was influenced by age. Further studies are required to assess the form of the retained Gd and to investigate the potential risks associated with Gd retention in bone marrow in juvenile animals treated with gadodiamide. Regardless of age, total Gd concentration in the brain and bone was 10- to 30-fold higher after administration of gadodiamide compared with gadoterate.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Fretellier N, Granottier A, Rasschaert M, et al. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats. Invest Radiol. 2019. PMID: 30394964. doi:10.1097/RLI.0000000000000517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。